Life-course of atopy and allergy-related disease events in tropical sub-Saharan Africa: A birth cohort study

listen audio

Study Justification:
– The study aimed to investigate the life-course of allergy-related diseases (ARDs) in a tropical, low-income environment, which is markedly different from high-income countries where ARDs have been extensively studied.
– Understanding the life-course of ARDs in tropical sub-Saharan Africa is important for developing effective prevention and management strategies in this region.
Study Highlights:
– The study followed Ugandan children from birth to 9 years and collected data on ARD symptoms and diagnoses.
– The prevalence of wheeze and eczema was high in infancy but decreased with age, with only 4% reporting recent wheeze, 5% eczema, and 5% rhinitis at 9 years.
– Atopy (positive skin prick test) prevalence increased from 19% at 3 years to 25% at 9 years.
– Atopy at 3 or 9 years was strongly associated with reported ARD events at 9 years.
– Reported or doctor-diagnosed ARD events in early childhood were associated with the same events in later childhood.
– The typical Atopic March, a sequential progression of ARDs, was not observed in this study.
Recommendations for Lay Reader and Policy Maker:
– The study highlights the importance of early identification and management of ARDs in tropical sub-Saharan Africa.
– Prevention strategies should focus on reducing environmental exposures that may contribute to the development of atopy and ARDs.
– Healthcare providers should be aware of the association between atopy and ARD events and consider early intervention for children with atopy.
– Further research is needed to understand the specific environmental factors that contribute to the development of ARDs in this region.
Key Role Players:
– Researchers and scientists involved in allergy and immunology research
– Healthcare providers and clinicians
– Public health officials and policymakers
– Community leaders and organizations
– Funding agencies and donors
Cost Items for Planning Recommendations:
– Research and data collection expenses
– Training and capacity building for healthcare providers
– Development and implementation of prevention and management programs
– Public health education and awareness campaigns
– Monitoring and evaluation of interventions
– Collaboration and coordination between different stakeholders

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is relatively strong, but there are some areas for improvement. The study design is a birth cohort study, which provides valuable longitudinal data. The sample size is large, with 2345 live-born children. The study uses validated questionnaires and doctor-diagnosed ARD events to gather data. The association between atopy and ARD events at 9 years is supported by odds ratios. However, the abstract does not provide information on the statistical significance of these associations. Additionally, the abstract does not mention any limitations of the study or potential confounding factors. To improve the evidence, the abstract should include p-values or confidence intervals for the odds ratios to assess statistical significance. It should also discuss any limitations or potential confounders that may affect the results.

Background: In high-income countries, allergy-related diseases (ARDs) follow a typical sequence, the ‘Atopic March’. Little is known about the life-course of ARDs in the markedly different, low-income, tropical environment. We describe ARDs in a tropical, African birth cohort. Methods: Ugandan children were followed from birth to 9 years. ISAAC questionnaires were completed at intervals; doctor-diagnosed ARDs were recorded throughout follow-up. Skin prick tests (SPTs) were performed at 3 and 9 years. Atopy was defined as ≥1 positive SPT. Results: Of the 2345 live-born children, 1214 (52%) were seen at 9 years. Wheeze and eczema were common in infancy, but by 9 years, only 4% reported recent wheeze, 5% eczema and 5% rhinitis. Between 3 and 9 years, atopy prevalence increased from 19% to 25%. Atopy at 3 or 9 years was associated with reported ARD events at 9 years, for example OR = 5.2 (95% CI 2.9–10.7) for atopy and recent wheeze at 9 years. Reported or doctor-diagnosed ARD events in early childhood were associated with the same events in later childhood, for example OR = 4.4 (2.3–8.4) for the association between reported wheeze before 3 years with reported recent wheeze at 9 years, but progression from early eczema to later rhinitis or asthma was not observed. Conclusion: Allergen sensitization started early in childhood and increased with age. Eczema and wheeze were common in infancy and declined with age. Atopy was strongly associated with ARD among the few affected children. The typical Atopic March did not occur. Environmental exposures during childhood may dissociate atopy and ARD.

The EMaBS is based in Entebbe municipality and Katabi subcounty, Wakiso district, Uganda: a peninsula on Lake Victoria, comprising urban, rural and fishing communities. Between 2003 and 2005, pregnant women were recruited into a randomized, double‐blind, placebo‐controlled trial of anthelminthic treatment in pregnancy and early childhood, and followed up as previously described [ISRCTN32849447] 9. The Research and Ethics Committee of the Uganda Virus Research Institute, the Uganda National Council for Science and Technology, and the London School of Hygiene and Tropical Medicine granted ethical approval. At ages 1, 2, 3, 5 and 9 years, caregivers were interviewed (in the child’s presence) on ARD symptoms using questions from the International Study on Allergy and Asthma in Children (ISAAC) questionnaire 15 and data on urticaria were also collected. For data collected at age 3 years, these questions were included in the questionnaire from November 2007 onwards; hence, only responses from children attending their age 3 visit from that date onwards were collected. Reported recent events were wheeze, eczema (a recurrent pruritic rash with typical infant or child distribution), allergic rhinitis (sneezing or runny nose or blocked nose, with itchy and watery eyes, without having a cold or ‘flu’) and urticaria (pruritic rash with wheals, ‘ebilogologo’ in the vernacular), occurring in the preceding 12 months. At 9 years, the questionnaire was supplemented with (i) the ISAAC video questionnaire (VQ; shown after the oral questionnaire [OQ]), and (ii) questions from the UK diagnostic criteria (UKDC) for atopic eczema 15. The VQ contained five short sequences of asthma symptoms (audible wheezing without breathlessness, exercise‐induced wheezing, waking at night with breathlessness, nocturnal coughing, a severe asthma attack). Each sequence was followed by questions asking whether the child’s breathing had ‘ever’ or ‘in the last 12 months’ been like the person’s in the video. Children were examined for visible flexural dermatitis by team members trained in the standardized approach 16. The UKDC defines eczema as a recent pruritic rash with at least three of the following: history of flexural involvement, history of generally dry skin, personal history of asthma or allergic rhinitis, visible flexural dermatitis and onset below age 2 years. Doctor‐diagnosed ARD events were identified when sick children presented to the study clinic. Wheezing episodes below the age of 5 years were documented. Asthma was diagnosed after the age of 5 years as an episode of wheezing or, a dry nocturnal cough, with a previous asthma‐like episode, after excluding other possible causes. Eczema was a recurrent pruritic rash lasting more than 6 months, with typical infant or child distributions. Skin prick testing was performed in a subset of three‐year‐olds (those who attained 3 years of age from November 2007 onwards, when SPT was added to the procedures performed at this visit) and in nine‐year‐olds, on the volar surface of the arm using standard methods 17 with allergens likely to elicit a response in this setting 18. At 3 years 12, dust mites (Dermatophagoides, Blomia tropicalis), cow’s milk and egg white were used; and at 9 years, the dust mites, German cockroach (Blattella germanica), peanut, Bermuda grass, cat, pollen and mould were used (ALK‐Abelló, Laboratory Specialities (Pty) Ltd, Randburg, South Africa). Wheals were measured after 15 min, positive being a mean diameter ≥3 mm. The primary definition of atopy was SPT positivity to at least one allergen (further categorized as monosensitivity [sensitive to one allergen] and polysensitivity [≥2 allergens]). At 9 years, plasma stored at −80°C was assessed for Dermatophagoides‐specific (Der‐p) IgE response using an in‐house ELISA as previously described 13. The lower detection limit was 312 ng/ml. A secondary definition of atopy was detectable Der‐p IgE >312 ng/ml. Data were double‐entered in Microsoft Access and analysed with Stata 14 (College Station, TX, USA). Chi‐square tests were used to compare maternal baseline (age, education, marital status, any worm infection, body mass index, anaemia) and child (sex, atopy at 3 years and infantile eczema diagnosis) characteristics between children seen and not seen at age 9 years. Agreement between OQ and VQ was determined by kappa statistic (κ) 19. Cross‐sectional associations between atopy and reported recent ARD events at 9 years were estimated using logistic regression and population‐attributable fraction (PAF) calculated. Longitudinal inter‐relationships between atopy or reported ARDs in the first 3 years of life (reported ARD event at 1, 2 or 3 years) and atopy or reported ARDs at 9 years were examined using logistic regression. Poisson regression with random effects was used to assess whether reported ARDs or doctor‐diagnosed ARD events in early childhood (0–5 years) or atopy at 3 years were associated with doctor‐diagnosed ARD events between 5 and 9 years.

Based on the provided information, here are some potential innovations that could be used to improve access to maternal health:

1. Telemedicine: Implementing telemedicine services can help overcome geographical barriers and provide access to healthcare services for pregnant women in remote areas. This technology allows pregnant women to consult with healthcare professionals through video calls, receive medical advice, and monitor their health remotely.

2. Mobile health (mHealth) applications: Developing mobile applications specifically designed for maternal health can provide pregnant women with important information, reminders, and access to healthcare resources. These apps can offer features such as tracking prenatal appointments, providing educational content, and sending alerts for medication reminders.

3. Community health workers: Training and deploying community health workers who can provide basic prenatal care, education, and support to pregnant women in underserved areas. These workers can help bridge the gap between healthcare facilities and pregnant women, ensuring they receive the necessary care and guidance throughout their pregnancy.

4. Mobile clinics: Establishing mobile clinics that travel to remote areas to provide prenatal care, screenings, and vaccinations. These clinics can bring healthcare services directly to pregnant women who may have limited access to transportation or healthcare facilities.

5. Health education programs: Implementing comprehensive health education programs that focus on maternal health, including prenatal care, nutrition, breastfeeding, and postnatal care. These programs can be conducted in community settings, schools, or through digital platforms to reach a wider audience.

6. Maternal health vouchers: Introducing voucher programs that provide pregnant women with financial assistance to access prenatal care, delivery services, and postnatal care. These vouchers can be distributed to women in low-income communities, ensuring they have the means to seek appropriate healthcare services.

7. Public-private partnerships: Collaborating with private healthcare providers to expand access to maternal health services. This can involve subsidizing costs, establishing referral systems, and improving the quality of care provided by private facilities.

8. Maternal health awareness campaigns: Launching awareness campaigns to educate communities about the importance of maternal health and the available services. These campaigns can help reduce stigma, increase awareness of available resources, and encourage pregnant women to seek timely care.

It’s important to note that the specific context and needs of the community should be considered when implementing these innovations to ensure their effectiveness and sustainability.
AI Innovations Description
Based on the provided information, the recommendation to improve access to maternal health is to focus on early identification and management of allergy-related diseases (ARDs) in children. This can be achieved through the following strategies:

1. Increase awareness: Educate pregnant women and caregivers about the signs and symptoms of ARDs, such as wheezing, eczema, allergic rhinitis, and urticaria. This will help them recognize these conditions early and seek appropriate medical care.

2. Strengthen healthcare systems: Ensure that healthcare facilities, especially in low-income, tropical environments, are equipped to diagnose and manage ARDs in children. This includes providing training to healthcare providers on recognizing and treating ARDs, as well as ensuring the availability of necessary medications and treatments.

3. Implement regular screenings: Conduct regular screenings for ARDs in children, starting from infancy. This can be done through the use of validated questionnaires, such as the International Study on Allergy and Asthma in Children (ISAAC) questionnaire, and skin prick tests (SPTs) to identify allergen sensitization.

4. Provide early intervention: Offer timely interventions, such as appropriate medications, allergen avoidance strategies, and lifestyle modifications, to children identified with ARDs. This will help prevent the progression of these conditions and improve overall health outcomes.

5. Foster collaboration: Encourage collaboration between healthcare providers, researchers, and policymakers to develop and implement evidence-based guidelines for the management of ARDs in children. This will ensure a comprehensive and coordinated approach to addressing these conditions.

By implementing these recommendations, access to maternal health can be improved by addressing the early identification and management of ARDs in children, ultimately leading to better health outcomes for both mothers and their children.
AI Innovations Methodology
To improve access to maternal health in the context of this study, here are some potential recommendations:

1. Mobile clinics: Implementing mobile clinics that can travel to remote areas and provide maternal health services, including antenatal care, postnatal care, and family planning.

2. Telemedicine: Utilizing telemedicine technologies to connect healthcare providers with pregnant women in rural areas, allowing them to receive consultations and guidance remotely.

3. Community health workers: Training and deploying community health workers who can provide basic maternal health services, education, and support in underserved areas.

4. Health education programs: Developing and implementing health education programs that focus on maternal health, including topics such as nutrition, prenatal care, and birth preparedness.

5. Transportation support: Establishing transportation support systems to ensure that pregnant women can easily access healthcare facilities, especially in remote areas with limited transportation options.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define indicators: Identify key indicators that measure access to maternal health, such as the number of pregnant women receiving antenatal care, the percentage of births attended by skilled health personnel, and the availability of emergency obstetric care.

2. Baseline data collection: Collect data on the current status of these indicators in the target population or area.

3. Model development: Develop a simulation model that incorporates the potential impact of the recommendations on the identified indicators. This could involve using statistical techniques, such as regression analysis or mathematical modeling, to estimate the expected changes in the indicators based on the implementation of the recommendations.

4. Sensitivity analysis: Conduct sensitivity analysis to assess the robustness of the model and explore different scenarios or assumptions. This can help identify the most influential factors and potential uncertainties in the simulation results.

5. Projection and evaluation: Use the simulation model to project the potential impact of the recommendations over a specific time period. Compare the projected indicators with the baseline data to evaluate the effectiveness of the recommendations in improving access to maternal health.

6. Iterative refinement: Refine the simulation model based on feedback and additional data, if available, to improve its accuracy and reliability.

By following this methodology, policymakers and healthcare providers can gain insights into the potential impact of different recommendations on improving access to maternal health and make informed decisions on which interventions to prioritize and implement.

Share this:
Facebook
Twitter
LinkedIn
WhatsApp
Email